Biomea Fusion, Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022. Financial statements are unaudited; amounts below are in U.S. dollars. Biomea is a clinical-stage biopharmaceutical company developing covalent small-molecule therapies. It has no approved products and has generated no revenue.
Financial performance and position
- Revenue and margins: No revenue was reported. Profitability and operating margins are not meaningful for this pre-commercial company.
- Q3 results: Research and development (R&D) expense was $18.2 million, general and administrative (G&A) expense was $5.2 million, and net loss was $22.9 million, or $0.78 per share. In Q3 2021, net loss was $12.6 million, or $0.43 per share.
- Nine-month results: R&D expense was $42.2 million, G&A was $15.2 million, and net loss was $56.5 million, or $1.93 per share. For the comparable 2021 period, net loss was $26.9 million, or $1.21 per share.
- Cash flow: Operating activities used $42.2 million in the first nine months of 2022, versus $19.5 million in 2021. Investing activities provided $28.0 million, primarily from investment maturities; financing activities provided $0.7 million, mainly from option exercises and employee stock purchases.
- Liquidity: At September 30, cash and cash equivalents were $132.3 million; cash, cash equivalents, restricted cash and investments totaled $133.8 million. Management believes resources will fund planned operations for at least one year past issuance of the statements. Accumulated deficit was $106.3 million.
- Debt and obligations: The company reported no interest-bearing liabilities. Operating lease liabilities totaled $2.4 million. A new office sublease expected to begin in January 2023 carries approximately $6.8 million in future rent payments and was not recognized as a lease asset or liability at quarter-end.
Material changes versus the prior comparable period
- Q3 R&D expense rose $10.4 million year over year; nine-month R&D rose $25.3 million. The company cited increased clinical and preclinical work, manufacturing activity, headcount and facilities costs.
- Q3 G&A increased $0.5 million; nine-month G&A increased $5.2 million, mainly due to personnel and public-company professional services.
- Net loss more than doubled for the nine-month period. Operating cash use also increased. In 2021, IPO proceeds of $152.8 million were a major financing source; there were no IPO proceeds in 2022.
- Cash and cash equivalents declined from $145.7 million at December 31, 2021 to $132.3 million at September 30, 2022, while short- and long-term investments fell from $29.7 million to $1.2 million.
Outlook, developments and risks
- Management expects operating losses and expenses to continue and increase as clinical programs advance. The filing provides no revenue or earnings guidance.
- BMF-219 was being evaluated in the Phase 1 COVALENT-101 trial in liquid tumors. After quarter-end, the company reported FDA clearance for the COVALENT-102 Phase 1/1b trial in KRAS-mutated solid tumors, and first-patient dosing in its CLL cohort and in the Phase 2 portion of the type 2 diabetes COVALENT-111 trial.
- BMF-500, an oral covalent FLT3 inhibitor candidate, was selected as a development candidate in May 2022. Management described diabetes and cancer findings for BMF-219 as preclinical; they do not establish clinical efficacy.
- On October 14, 2022, the company filed a shelf registration statement for up to $350 million of securities; it became effective October 24. No securities had been issued under it and no proceeds received as of the filing.
- Principal risks include early-stage clinical and regulatory uncertainty, dependence on BMF-219, need for substantial future capital, reliance on third-party manufacturers and research providers, competition, potential safety issues, and possible disruption from COVID-19, supply chains and adverse economic conditions.
- The company reported no material legal proceedings and no subsequent events in the financial-statement note. Management concluded disclosure controls were effective at a reasonable assurance level; no material change in internal control over financial reporting was identified during the quarter.
Important facts for investors to verify
- Current cash burn and whether the stated runway remains adequate as clinical and manufacturing spending expands.
- Clinical-trial enrollment, safety, dose selection and data for BMF-219; distinguish human trial results from preclinical claims.
- Funding plans and potential dilution or other terms if the company uses its $350 million shelf registration.
- Timing, costs and obligations for the new office sublease and additional laboratory capacity.
- Any changes in manufacturing supply, trial timelines, regulatory feedback or risk disclosures since this quarter-end.